Venmax Drugs and Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals Ltd submitted its Annual Report for the Financial Year 2025-26, including the Notice of 37th Annual General Meeting, to be held on September 26, 2026. The report includes the Standalone Audited Financial Statements, the Report of the Directors, and the Independent Auditor's Report.

Venmax Drugs and Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals Ltd has announced the outcome of its Board Meeting, which included the approval of the Notice and Directors Report for the Financial Year 2025-2026, Secretarial Audit Report, and the date, time, and venue of the 37th Annual General Meeting. The Board also approved the appointment of Mr. Venkata Rao Sadhanala as Managing Director and the regularization of Mrs. Padmaja Kalyani Sadhanala and Mr. Revoor Ramachandra as Non-Executive Directors.

Venmax Drugs and Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/08/2026 to consider and approve matters related to the 37th Annual General Meeting, regularization of appointment of Additional Directors, and change in designation of the Whole-time Director.

Venmax Drugs and Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals Ltd has published unaudited financial results for the quarter ended June 30, 2026, as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Venmax Drugs and Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals Ltd has filed a statement confirming that there is no deviation or variation in the use of proceeds raised through a preferential issue for the quarter ended June 30, 2026.

Venmax Drugs and Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals Ltd has announced unaudited financial results for the quarter ended June 30, 2026, along with a limited review report from its statutory auditors. The company has also approved the forfeiture of 7,80,001 partly paid-up convertible share warrants due to non-payment of the balance subscription amount within the prescribed period.

Venmax Drugs and Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, along with a limited review report from its statutory auditors. The company has also approved the forfeiture of 7,80,001 partly paid-up convertible share warrants due to non-payment of the balance subscription amount within the prescribed period.

Venmax Drugs and Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals Ltd has scheduled a board meeting on August 7, 2026, to consider and approve unaudited financial results for the quarter ended June 30, 2026, and to consider the forfeiture of partly paid-up share warrants.

Venmax Drugs and Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals Ltd has allotted 7,53,334 equity shares to a warrant holder, Dinesh Muddu Kotian, at an issue price of Rs. 20 per share, increasing the company's paid-up capital to Rs. 14,48,39,290.

Venmax Drugs and Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals Ltd has allotted 21,47,665 equity shares to 8 warrant holders on a preferential basis, increasing the company's paid-up capital to Rs. 13,73,05,950.